Conditionally replicative adenoviruses (CRAds) represent an important novel approach for cancer therapy. CRAd agents are designed to specifically replicate in and kill tumor cells to yield an effective yet safe therapeutic outcome. Although their great potential have awarded them rapid translation into human clinical trials where the safety of CRAds have been clearly highlighted, little data have been obtained with regards to the critical functions of CRAds efficient infection of tumor cells, tumor-specific replication, and lateral spread. Without deeper understanding of the nature of these replicative agents especially in a patient context, further development of CRAds would be greatly hindered. The crux of a general dilemma in the virotherapy field is lack of a monitoring system compatible with replicative agents. Unfortunately, the bulk of gene therapy vector detection schemes have been specifically designed for the assessment of gene expression. These modalities are not suitable for the monitoring of CRAds because of the very nature of their program to kill infected tumor cells, a concept at odds with the notion of viable transgene expression. Furthermore, reporters by themselves cannot accurately depict the underlying level of replication as well as true physical distribution of viral progeny, two crucial functions of replicative agents. Clinical trials to date have had to rely on traditional histological analysis of biopsy specimens which are error-prone and cannot portray the multiplicative nature of CRAds. The ideal monitoring system for CRAds should embody the following features: (1) report the level of viral replication, (2) allow direct detection of viral spread, (3) permit dynamic detection of viral activity, (4) minimally perturb replication and spread efficiency of the virus, and (5) possess the power for noninvasive detection. To address this issue, we hypothesized that a genetic adenovirus labeling system using a structural reporter fusion protein would dynamically represent viral replication and spread. We propose adenovirus capsid labeling with IX-EGFP and core labeling with mu-EGFP, V-EGFP, and VII-EGFP. It is evident that a monitoring system for CRAds is needed for advancing the field. A genetic structural labeling system for adenovirus would offer noninvasive dynamic detection of replication and spread. Not only would this system be indispensable in developing advanced CRAds, it would also be applicable for monitoring CRAd therapy in patients. ? ?
| Mathis, J Michael; Bhatia, Shilpa; Khandelwal, Alok et al. (2011) Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging. PLoS One 6:e16792 |
| Li, Jing; Fatima, Aiman; Komarova, Svetlana et al. (2010) Evaluation of adenovirus capsid labeling versus transgene expression. Virol J 7:21 |
| Ugai, Hideyo; Wang, Minghui; Le, Long P et al. (2010) In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection. J Mol Biol 395:55-78 |
| Pérez-Berná, Ana J; Marabini, Roberto; Scheres, Sjors H W et al. (2009) Structure and uncoating of immature adenovirus. J Mol Biol 392:547-57 |
| Cody, J J; Douglas, J T (2009) Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 16:473-88 |
| Tang, Yizhe; Wu, Hongju; Ugai, Hideyo et al. (2009) Derivation of a triple mosaic adenovirus for cancer gene therapy. PLoS One 4:e8526 |
| Schoehn, Guy; El Bakkouri, Majida; Fabry, Celine M S et al. (2008) Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol 82:3192-203 |
| Wu, Hongju; Curiel, David T (2008) Fiber-modified adenoviruses for targeted gene therapy. Methods Mol Biol 434:113-32 |
| Tang, Yizhe; Le, Long P; Matthews, Qiana L et al. (2008) Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 377:391-400 |
| San Martin, Carmen; Glasgow, Joel N; Borovjagin, Anton et al. (2008) Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. J Mol Biol 383:923-34 |
Showing the most recent 10 out of 24 publications
